Literature DB >> 6478416

Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group.

M H Gail, R T Eagan, R Feld, R Ginsberg, B Goodell, L Hill, E C Holmes, J M Lukeman, C F Mountain, R K Oldham.   

Abstract

The authors present prognostic information on recurrence and survival for resected Stage I lung cancer patients with squamous cell carcinoma, adenocarcinoma or large cell carcinoma. The data derive from 392 carefully staged patients and include results from the history and physical examination, preoperative laboratory tests, nature of the surgery, complications, initial pathologic findings following surgical resection, and final pathologic review. A simple multivariate model of recurrence, which is used to classify patients into low, intermediate, and high-risk groups, is based on tumor size and location (T1, T2), histologic type (squamous, nonsquamous/mixed) and nodal status (N0, N1). To model survival, the performance status and the presence of empyema, pneumonia, or wound infection were added to the previous factors. Not all factors associated with increased mortality are associated with increased risk of recurrence, and, in particular, postoperative empyema, pneumonia or wound infections carry an increased risk of death only. Serial measurements of performance status and leukocyte count have the potential for monitoring for increased risk of recurrence and death.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6478416     DOI: 10.1002/1097-0142(19841101)54:9<1802::aid-cncr2820540908>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

1.  Management of solitary pulmonary nodules: how do thoracic computed tomography and guided fine needle biopsy influence clinical decisions?

Authors:  D R Baldwin; T Eaton; J Kolbe; T Christmas; D Milne; J Mercer; E Steele; J Garrett; M L Wilsher; A U Wells
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

2.  Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.

Authors:  Xiaofei Wang; Lin Gu; Ying Zhang; Daniel J Sargent; William Richards; Apar Kishor Ganti; Jeffery Crawford; Harvey Jay Cohen; Thomas Stinchcombe; Everett Vokes; Herbert Pang
Journal:  Lung Cancer       Date:  2015-08-18       Impact factor: 5.705

3.  [Does cigarette smoking influence the survival of patients with prostate cancer?].

Authors:  T Jäger; A Eisenhardt; H Rübben; G Lümmen
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

Review 4.  Radical sublobar resection for lung cancer.

Authors:  Morihito Okada
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-04-10

5.  [Survival time of exclusively irradiated NSCLC patients: the viewpoint of a clinical biologist. Concerning the article by R. Wilhelm et al in Strahlenther Onkol 1988: 174:128-32 (No. 3)].

Authors:  J Watine; R Fintelmann; J C Charet
Journal:  Strahlenther Onkol       Date:  1999-01       Impact factor: 3.621

6.  Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.

Authors:  Stephen L Graziano; Lin Gu; Xiaofei Wang; Arthur H Tatum; Robin T Vollmer; Gary M Strauss; Robert Kratzke; Arkadiusz Z Dudek; Everett E Vokes; Mark R Green
Journal:  J Thorac Oncol       Date:  2010-06       Impact factor: 15.609

7.  Tobacco-use Cessation Counseling Service Usage.

Authors:  Pramit A Nadpara; S Suresh Madhavan; Cindy Tworek
Journal:  W V Med J       Date:  2016 Sep-Oct

Review 8.  Nutrition in cancer patients.

Authors:  S Mercadante
Journal:  Support Care Cancer       Date:  1996-01       Impact factor: 3.603

Review 9.  Lung cancer--current concepts and controversies.

Authors:  S B Pett; J A Wernly; B F Akl
Journal:  West J Med       Date:  1986-07

10.  Smoking behavior following diagnosis in patients with stage I non-small cell lung cancer.

Authors:  E R Gritz; R Nisenbaum; R E Elashoff; E C Holmes
Journal:  Cancer Causes Control       Date:  1991-03       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.